The North America Theranostics Market is experiencing robust growth, driven by technological advancements in personalized medicine and increasing demand for targeted therapies. Valued at USD 2,950 Million in 2025, the market is expected to reach USD 10,360 Million by 2035, expanding at a CAGR of 12.2% from 2024 to 2035. Companies like GE Healthcare and Siemens Healthineers are at the forefront of developing innovative theranostic solutions that integrate diagnostics with therapeutics to improve patient outcomes in oncology and other chronic conditions.
The economic impact of tariffs on "North America Theranostics Market".
North America Theranostics Market Growth Drivers
Technological Advancements in Imaging and Biomarker Discovery: Leading companies such as GE Healthcare have been investing heavily in AI-driven imaging platforms and novel biomarker identification, which enhance early detection and allow for more precise targeting of therapeutics. The integration of advanced PET/CT and PET/MRI systems, coupled with companion diagnostics, is enabling clinicians to tailor therapies more effectively, driving market growth significantly.
Rising Prevalence of Cancer and Chronic Diseases: Siemens Healthineers highlighted in 2023 that the sharp rise in cancer incidences across North America has led to an increased adoption of theranostic approaches in oncology, where theranostics delivers both diagnostic and therapeutic benefits in a single platform. This dual-use capability is resulting in faster, more personalized cancer treatment pathways, thus fueling market expansion.
North America Theranostics Market Trends
Growing Adoption of Radiopharmaceuticals: Companies like Cardinal Health have recently expanded their radiopharmaceutical manufacturing capacity to meet the surging demand for targeted therapies in oncology, neurology, and cardiology. This trend is propelled by the clinical success of radioligand therapies that deliver precisely targeted radiation to tumors, minimizing collateral damage and improving efficacy.
Integration of Artificial Intelligence (AI) and Machine Learning: The incorporation of AI by players such as IBM Watson Health into theranostic workflows is revolutionizing personalized medicine by enabling more accurate interpretation of diagnostic imaging, patient stratification, and predictive analytics for treatment response. These advancements are optimizing theranostic solutions for both providers and patients.
North America Theranostics Market Opportunities
Expansion into Rare Disease Theranostics: Companies like Lantheus Holdings are exploring expansion into rare disease indications, which represent a largely untapped market for theranostics. With increasing regulatory incentives for orphan drug development, this area offers significant growth potential.
Collaborative Research and Public-Private Partnerships: Organizations such as Mayo Clinic are engaging in collaborations with biotech startups to accelerate the development of new theranostic agents, capitalizing on shared expertise and resources to bring novel therapies to market faster.
North America Theranostics Market Revenue (USD Million), 2020-2035
The revenue chart illustrates a consistent upward trajectory in the North America Theranostics Market from 2020 to 2035. In 2020, the market size stood at USD 1,120 Million, growing steadily each year as technological innovations, regulatory approvals, and the rising adoption of precision medicine propel industry growth. By 2025, the market reached USD 2,950 Million. The acceleration is notable after 2028 when a wave of next-generation radiopharmaceuticals and AI-enabled diagnostics enters the market, resulting in a projected revenue of USD 10,360 Million in 2035. This substantial growth highlights the region's readiness to adopt advanced theranostic solutions and the ongoing investment by key stakeholders.
North America Theranostics Market Share by Region (%), 2025
The 2025 regional breakdown of the North America Theranostics Market is led by the United States, accounting for 78% of the market share, driven by advanced healthcare infrastructure, major industry players, and higher adoption rates. Canada follows with 14%, benefiting from rising investments in precision medicine and academic collaborations. Mexico holds a 5% share, showing gradual progression through public-private partnerships and healthcare reforms. The 'Others' category, including the Caribbean and Central American territories, collectively represents 3%. The dominance of the U.S. is set to remain as regulatory support and technological innovation continue to drive growth.
Recent Developments in the North America Theranostics Market
In May 2024, GE Healthcare announced the U.S. FDA approval of its new PET radiopharmaceutical for prostate cancer theranostics, which combines diagnostic imaging with targeted radiotherapeutic properties. This marks a pivotal milestone for GE Healthcare, enabling clinicians to simultaneously detect and treat metastatic prostate lesions, enhancing patient care and outcomes.
In April 2024, Lantheus Holdings, in partnership with Curium, launched a first-in-class radioligand therapy targeting neuroendocrine tumors in both U.S. and Canadian markets. This collaborative effort underscores the growing trend of strategic alliances to accelerate theranostic innovation, leveraging shared assets to reach patients faster.
In March 2024, Siemens Healthineers expanded its theranostics service network by opening a specialized center in Texas, dedicated to next-generation personalized oncology solutions. This facility offers integrated diagnostic and therapeutic services, incorporating AI-driven analysis and advanced imaging technologies, setting a new benchmark in patient-specific treatment pathways.
Press Releases